The popularity of several new prescription products in has fostered debate on numerous clinical, economic, and health policy issues. At the Managed Care Summit in 2002, health plan medical and pharmacy directors discussed these issues and listened to presentations about the implications of the rise of previously unheralded therapeutic classes.
The Shaping of Health Care Policy
The Value of Atypical Antipsychotics in the Treatment of Schizophrenia
Impact of Proton Pump Inhibitor Utilization Patterns on Gastroesophageal Reflux Disease-Related Costs